mRNA Cancer Immunotherapy Setback: BNT113 Misses Endpoint
An mRNA cancer immunotherapy, BioNTech’s BNT113, missed its PFS goal in head and neck cancer. Overall survival is still being assessed. What it means.
Tag: BioNTech cancer vaccine
Read More